ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the completion of the transaction, the insider now owns 1,098,499 shares in the company, valued at $12,819,483.33. This represents a 8.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, December 10th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.16, for a total value of $1,316,000.00.
• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.88, for a total value of $1,488,000.00.

ARS Pharmaceuticals Stock Performance

Shares of ARS Pharmaceuticals stock opened at $11.32 on Friday. The company has a market capitalization of $1.10 billion, a PE ratio of -22.20 and a beta of 0.88. The company has a 50-day simple moving average of $14.44 and a two-hundred day simple moving average of $12.42. ARS Pharmaceuticals, Inc. has a one year low of $5.02 and a one year high of $18.51.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SPRY. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Finally, Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $24.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. J.W. Cole Advisors Inc. grew its stake in ARS Pharmaceuticals by 10.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after buying an additional 1,500 shares during the last quarter. nVerses Capital LLC acquired a new stake in ARS Pharmaceuticals in the third quarter worth about $30,000. Creative Planning grew its stake in shares of ARS Pharmaceuticals by 7.0% during the third quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after acquiring an additional 2,307 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of ARS Pharmaceuticals by 18.2% during the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after acquiring an additional 4,369 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ARS Pharmaceuticals by 151.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after acquiring an additional 4,472 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.